Charles River uses its adenoviral technology to elucidate the mechanism of action of small molecules. By combining the compound of interest with knockdown or overexpression of candidate gene in the same phenotypic assay, we can start to elucidate the mechanism of action of the compound(s).
In addition, we are able to access our other technologies to perform mode-of-action studies:
Use of our in-house chemogenomics database to predict candidate targets
Cross-screening of compounds of interest through panels of biochemical and cell-based assays linked by candidate pathways or candidate gene families
Biophysical assays to look for compound binding to candidate target proteins – SPR, size exclusion chromatography, X-ray crystallography